Opthea (ASX:OPT) requested that its securities be placed in trading halt until an announcement related to results of its Phase 3 Combination OPT-302 with Aflibercept Study (COAST) clinical trial is made, according to a Monday filing with the Australian bourse.
The trading halt will remain in place until the start of trading on March 19 or when the company makes the announcement about the COAST results, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.